Clinical Trials
453 trialsNCT03089554 2026-05-27
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
University of Kentucky
Phase 2 Recruiting
NCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT04181463 2026-05-27
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT06311214 2026-05-27
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07209111 2026-05-26
KANDLELIT-014
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04449549 2026-05-22
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05554380 2026-05-22
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05977998 2026-05-22
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06788938 2026-05-18
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07594431 2026-05-18
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Stanford University
Phase 2 Not yet recruiting
NCT05656651 2026-05-15
ACTIVE
Universität Duisburg-Essen
Phase 2 Active not recruiting
NCT05879146 2026-05-15
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05554341 2026-05-14
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03907475 2026-05-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05327010 2026-05-13
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05638295 2026-05-13
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06979596 2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05968326 2026-05-11
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT06559228 2026-05-08
ConnectedNest: a Digital Platform Connecting Individuals With Cancer to Social Care
University of Minnesota
Phase 2 Active not recruiting
NCT06936748 2026-05-05
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
Second Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT03752333 2026-05-04
CUPem
Imperial College London
Phase 2 Completed
NCT03872427 2026-05-04
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06416007 2026-05-04
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
University of Cincinnati
Phase 2 Recruiting
NCT06417190 2026-05-04
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07562581 2026-05-01
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2 Not yet recruiting
NCT04068649 2026-04-30
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT07041788 2026-04-30
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Second Affiliated Hospital of Nanchang University
Phase 2 Not yet recruiting
NCT03310879 2026-04-29
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03964727 2026-04-28
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT06010342 2026-04-28
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Teligene US
Phase 2 Recruiting
NCT04116541 2026-04-24
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT04752137 2026-04-24
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Massachusetts General Hospital
Phase 2 Recruiting
NCT05219435 2026-04-24
VEXILLUM
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT04452955 2026-04-22
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte Ltd
Phase 2 Active not recruiting
NCT06731933 2026-04-20
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Stanford University
Phase 2 Recruiting
NCT07540650 2026-04-20
pRevenT
Institute of Oncology Ljubljana
Phase 2 Not yet recruiting
NCT04879121 2026-04-16
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02387905 2026-04-15
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04957615 2026-04-15
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05347212 2026-04-15
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06669572 2026-04-15
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT05821556 2026-04-14
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06319378 2026-04-13
CAPSI
Section for Affective Disorders; Northern Stockholm Psychiatry
Phase 2 Recruiting
NCT06790602 2026-04-09
SWITCH
University of California, San Diego
Phase 2 Recruiting
NCT04847466 2026-04-08
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05993299 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06703346 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT07284589 2026-04-08
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT07346209 2026-04-08
STRIPe
University of California, San Diego
Phase 2 Not yet recruiting
NCT06593522 2026-04-07
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Amgen
Phase 2 Recruiting